226 related articles for article (PubMed ID: 19479667)
1. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
Jones T
Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
[TBL] [Abstract][Full Text] [Related]
2. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
4. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
5. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
8. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
10. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
11. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
Chu DW; Hwang SJ; Lim FS; Oh HM; Thongcharoen P; Yang PC; Bock HL; Dramé M; Gillard P; Hutagalung Y; Tang H; Teoh YL; Ballou RW;
Vaccine; 2009 Dec; 27(52):7428-35. PubMed ID: 19683087
[TBL] [Abstract][Full Text] [Related]
13. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
14. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
16. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
Leroux-Roels G
Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
[TBL] [Abstract][Full Text] [Related]
17. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
Hasegawa H; Ichinohe T; Tamura S; Kurata T
Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
Chada KE; Forshee R; Golding H; Anderson S; Yang H
Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs.
De Vleeschauwer AR; Baras B; Kyriakis CS; Jacob V; Planty C; Giannini SL; Mossman S; Van Reeth K
Vaccine; 2012 Aug; 30(37):5557-63. PubMed ID: 22727727
[TBL] [Abstract][Full Text] [Related]
20. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
